Table 2.
Total opioid consumption
| Control (CSE only) | Treatment (CSE with LPB) | P value | |
|---|---|---|---|
| Total morphine equivalent—oral opioid use only (mg) | 47 ± 30 | 41 ± 25 | 0.251 |
| Total morphine equivalent—PCA use only (mg) | 23 ± 14 | 19 ± 10 | 0.113 |
| Total morphine equivalent—PCA and oral opioid use (mg) | 71 ± 37 | 60 ± 33 | 0.150 |
| Number of patients using antiemetics over 48 h following surgery | 19 (43%) | 20 (43%) | 0.977 |
| Number of patients using antipruitics over 48 h following surgery | 10 (23%) | 15 (33%) | 0.295 |
| Number of patients reporting nausea (POD-1) | 11 (25%) | 14 (30%) | 0.565 |
| Number of patients reporting nausea (POD-2) | 7 (16%) | 7 (15%) | 0.928 |
| Number of patients reporting itching (POD-1) | 14 (32%) | 14 (30%) | 0.887 |
| Number of patients reporting itching (POD-2) | 5 (11%) | 5 (11%) | 0.941 |
Consumption of opioids, antiemetics, antipruritics, and incidence of nausea and itching among patients undergoing total hip arthroplasty by groups. Data presented as mean ± standard deviation. P values calculated using Mann–Whitney U test (continuous variables) and chi-square test (categorical variables)
CE combined spinal–epidural anesthesia, LPB lumbar plexus block